Clinical Trial Update: Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is investigating tucidinostat plus azacitidine and CHOP versus CHOP alone in untreated peripheral T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Tucidinostat (tucidinostat)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: T-cell Lymphoma | Phase 3 | Status: RECRUITING